Table 1.
Index treatment selected for the CORAL follow-up population
| Index treatment of CORAL follow-up FAS* | Unadjusted analyses | Adjusted analyses |
|---|---|---|
| CORAL follow-up (N = 170) | CORAL follow-up (N = 145) | |
| Any chemotherapy (monotherapy or combination) | 151 (88.82%) | 136 (93.79%) |
| Immunotherapy | 49 (28.82%) | 44 (30.34%) |
| Rituximab-based treatment | 48 (28.24%) | 43 (29.66%) |
| Ofatumumab-based treatment | 1 (0.59%) | 1 (0.69%) |
| Lenalidomide-based treatment | 1 (0.59%) | 1 (0.69%) |
| alloHCT | 19 (11.18%) | 16 (11.03%) |
| Best supportive care | 7 (4.12%) | 6 (4.14%) |
| Index treatment of CORAL follow-up ITT* | Unadjusted analyses | Adjusted analyses |
|---|---|---|
| CORAL follow-up (N = 205) | CORAL follow-up (N = 205) | |
| Without documented 3L+ index treatments | 21 (10.24%) | 21 (10.24%) |
| With documented 3L+ treatments | ||
| Any chemotherapy (monotherapy or combination) | 140 (76.09%) | 143 (77.72%) |
| Immunotherapy | 45 (24.46%) | 45 (24.46%) |
| Rituximab-based treatment | 44 (23.91%) | 44 (23.91%) |
| Ofatumumab-based treatment | 1 (0.54%) | 1 (0.54%) |
| Lenalidomide-based treatment | 1 (0.54%) | 1 (0.54%) |
| alloHCT | 19 (10.33%) | 19 (10.33%) |
| Best supportive care | 7 (3.80%) | 6 (3.26%) |
*
Some patients received >1 treatment in the same line of therapy; therefore, the categories are not mutually exclusive. Brentuximab vedotin, ibrutinib, axi-cel, and polatuzumab vedotin were also considered as potential index treatments; however, no patients received these therapies.